Dependence of Paclitaxel Sensitivity on a Functional Spindle Assembly Checkpoint

Cancer Research

Volumn 64, Issue 7, 2004, Pages 2502-2508

  Sudo, Tamotsu ^a   Nitta, Masayuki ^b   Saya, Hideyuki ^b   Ueno, Naoto T ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BUB1 RELATED PROTEIN; CYCLIN DEPENDENT KINASE 1; PACLITAXEL; PROTEIN MAD2;

ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; DRUG MECHANISM; EMBRYO; ENZYME ACTIVITY; GENE OVEREXPRESSION; GENE REPRESSION; HUMAN; HUMAN CELL; MICROTUBULE; MITOSIS; PRIORITY JOURNAL; PROTEIN FUNCTION; SPINDLE CELL;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CALCIUM-BINDING PROTEINS; CDC2 PROTEIN KINASE; CELL CYCLE PROTEINS; CELL LINE; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; HUMANS; MITOTIC SPINDLE APPARATUS; PACLITAXEL; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; REPRESSOR PROTEINS; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 1942474378     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-2013     Document Type: Article

References (38)

1. Eifel P, Axelson JA, Costa J, et al. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst (Bethesda) 2001;93:979-89.
2. Holmes FA, Walters RS, Theriault RL, et al. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst (Bethesda) 1991;83:1797-1805.
3. Nabholtz JM, Gelmon K, Bontenbal M, et al. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 1996;14:1858-67.
4. Bishop JF, Dewar J, Toner GC, et al. Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. J Clin Oncol 1999;17:2355-64.
5. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
6. Piccart MJ, Bertelsen K, James K, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst (Bethesda) 2000;92:699-708.
7. Tang C, Willingham MC, Reed JC, et al. High levels of p26BCL-2 oncoprotein retard taxol-induced apoptosis in human pre-B leukemia cells. Leukemia 1994;8:1960-9.
8. Huang Y, Ibrado AM, Reed JC, et al. Co-expression of several molecular mechanisms of multidrug resistance and their significance for paclitaxel cytotoxicity in human AML HL-60 cells. Leukemia 1997;11:253-7.
9. Giannakakou P, Sackett DL, Kang YK, et al. Paclitaxel-resistant human ovarian cancer cells have mutant β-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 1997;272:17118-25.
10. Yu D, Jing T, Liu B, et al. Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase. Mol Cell 1998;2:581-91.
11. Yu H. Regulation of APC-Cdc20 by the spindle checkpoint. Curr Opin Cell Biol 2002;14:706-14.
12. Li Y, Benezra R. Identification of a human mitotic checkpoint gene: hsMAD2. Science (Wash D C) 1996;274:246-8.
13. Jin DY, Spencer F, Jeang KT. Human T cell leukemia virus type I oncoprotein Tax targets the human mitotic checkpoint protein MAD1. Cell 1998;93:81-91.
14. Taylor SS, Ha E, McKeon F. The human homologue of Bub3 is required for kinetochore localization of Bub1 and a Mad3/Bub1-related protein kinase. J Cell Biol 1998;142:1-11.
15. Chan GK, Jablonski SA, Sudakin V, Hittle JC, Yen TJ. Human BUBR1 is a mitotic checkpoint kinase that monitors CENP-E functions at kinetochores and binds the cyclosome/APC. J Cell Biol 1999;146:941-54.
16. Fang G, Yu H, Kirschner MW. The checkpoint protein MAD2 and the mitotic regulator CDC20 form a ternary complex with the anaphase-promoting complex to control anaphase initiation. Genes Dev 1998;12:1871-83.
17. Sudakin V, Chan GK, Yen TJ. Checkpoint inhibition of the APC/C in HeLa cells is mediated by a complex of BUBR1, BUB3, CDC20, and MAD2. J Cell Biol 2001;154:925-36.
18. Tang Z, Bharadwaj R, Li B, Yu H. Mad2-Independent inhibition of APCCdc20 by the mitotic checkpoint protein BubR1. Dev Cell 2001;1:227-37.
19. Fang G. Checkpoint protein BubR1 acts synergistically with Mad2 to inhibit anaphase-promoting complex. Mol Biol Cell 2002;13:755-66.
20. Nigg EA. Mitotic kinases as regulators of cell division and its checkpoints. Nat Rev Mol Cell Biol 2001;2:21-32.
21. Meikrantz W, Schlegel R. Suppression of apoptosis by dominant negative mutants of cyclin-dependent protein kinases. J Biol Chem 1996;271:10205-9.
22. Shen SC, Huang TS, Jee SH, Kuo ML. Taxol-induced p34cdc2 kinase activation and apoptosis inhibited by 12-O-tetradecanoylphorbol-13-acetate in human breast MCF-7 carcinoma cells. Cell Growth Differ 1998;9:23-9.
23. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 1998;95:2509-14.
24. Takahashi T, Haruki N, Nomoto S, Masuda A, Saji S, Osada H. Identification of frequent impairment of the mitotic checkpoint and molecular analysis of the mitotic checkpoint genes, hsMAD2 and p55CDC, in human lung cancers. Oncogene 1999;18:4295-300.
25. Wang X, Jin DY, Wong YC, et al. Correlation of defective mitotic checkpoint with aberrantly reduced expression of MAD2 protein in nasopharyngeal carcinoma cells. Carcinogenesis 2000;21:2293-7.
26. Wang X, Jin DY, Ng RW, et al. Significance of MAD2 expression to mitotic checkpoint control in ovarian cancer cells. Cancer Res 2002;62:1662-8.
27. Dobles M, Liberal V, Scott ML, Benezra R, Sorger PK. Chromosome missegregation and apoptosis in mice lacking the mitotic checkpoint protein Mad2. Cell 2000;101:635-45.
28. Kalitsis P, Earle E, Fowler KJ, Choo KH. Bub3 gene disruption in mice reveals essential mitotic spindle checkpoint function during early embryogenesis. Genes Dev 2000;14:2277-82.
29. Luo X, Tang Z, Rizo J, Yu H. The Mad2 spindle checkpoint protein undergoes similar major conformational changes upon binding to either Mad1 or Cdc20. Mol Cell 2002;9:59-71.
30. Tanaka K, Nishioka J, Kato K, et al. Mitotic checkpoint protein hsMAD2 as a marker predicting liver metastasis of human gastric cancers. Jpn J Cancer Res 2001;92:952-8.
31. Michel LS, Liberal V, Chatterjee A, et al. MAD2 haplo-insufficiency causes premature anaphase and chromosome instability in mammalian cells. Nature (Lond) 2001;409:355-9.
32. Chen RH, Shevchenko A, Mann M, Murray AW, Spindle checkpoint protein Xmad1 recruits Xmad2 to unattached kinetochores. J Cell Biol 1998;143:283-95.
33. Waters JC, Chen RH, Murray AW, Salmon ED. Localization of Mad2 to kinetochores depends on microtubule attachment, not tension. J Cell Biol 1998;141:1181-91.
34. Cahill DP, Lengauer C, Yu J, et al. Mutations of mitotic checkpoint genes in human cancers. Nature (Lond) 1998;392:300-3.
35. Nakagawa H, Yokozaki H, Ouc N, et al. No mutations of the Bub1 gene in human gastric and oral cancer cell lines. Oncol Rep 2002;9:1229-32.
36. Saeki A, Tamura S, Ito N, et al. Frequent impairment of the spindle assembly checkpoint in hepatocellular carcinoma, Cancer (Phila) 2002;94:2047-54.
37. Sato M, Sekido Y, Horio Y, et al. Infrequent mutation of the hBUB1 and hBUBR1 genes in human lung cancer. Jpn J Cancer Res 2000;91:504-9.
38. Haruki N, Saito H, Harano T, et al. Molecular analysis of the mitotic checkpoint genes BUB1, BUBR1 and BUB3 in human lung cancers. Cancer Lett 2001;162:201-5.